Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Accumulated Depreciation (2021 - 2024)

Kezar Life Sciences' Accumulated Depreciation history spans 4 years, with the latest figure at $6.2 million for Q3 2024.

  • For Q3 2024, Accumulated Depreciation changed N/A year-over-year to $6.2 million; the TTM value through Sep 2024 reached $6.2 million, changed N/A, while the annual FY2023 figure was $5.4 million, 17.77% up from the prior year.
  • Accumulated Depreciation for Q3 2024 was $6.2 million at Kezar Life Sciences, up from $5.4 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $6.2 million in Q3 2024 and bottomed at $3.4 million in Q3 2021.
  • The 4-year median for Accumulated Depreciation is $4.5 million (2022), against an average of $4.6 million.
  • The largest annual shift saw Accumulated Depreciation increased 28.91% in 2022 before it grew 17.77% in 2023.
  • A 4-year view of Accumulated Depreciation shows it stood at $3.7 million in 2021, then rose by 26.01% to $4.6 million in 2022, then increased by 17.77% to $5.4 million in 2023, then rose by 14.41% to $6.2 million in 2024.
  • Per Business Quant, the three most recent readings for KZR's Accumulated Depreciation are $6.2 million (Q3 2024), $5.4 million (Q4 2023), and $5.1 million (Q2 2023).